An Israeli coronavirus drug that claims to have a 100% success rate among severely ill patients is being tested in the United States for the first time.
The trial comes after Pluristem Therapeutics Inc., a biotech company based in Haifa, reported last week that seven patients who were at a high risk of death due to respiratory failure survived after receiving the medication.
The patients were approved for treatment under the compassionate use program and exhibited respiratory failure requiring intubation in the ICU. Four of the patients had multi-system organ failure, including heart and kidney failure.
The seven patients were treated with Pluristem’s allogeneic placental expanded (PLX) cells. Essentially, these cells can potentially suppress or reverse the dangerous over-activation of the immune system that causes death in many coronavirus patients.
All seven of the patients who received the drug survived and four patients saw an improvement in respiration. One patient is still alive but saw a continued deterioration of their respiratory system.
Read more here: https://www.charismanews.com/opinion/standing-with-israel/80799-israeli-covid-19-treatment-with-100-survival-rate-tested-on-first-us-patient?utm_source=Standing%20With%20Israel&utm_medium=email&utm_content=subscriber_id:981077&utm_campaign=SWI%20-%202020-04-17